Blood pressure in Native Americans switched from celecoxib to rofecoxib

Annals of Pharmacotherapy

Volumn 39, Issue 5, 2005, Pages 797-802

  Fredy, Jefferson ^b,c   Diggins Jr , Daniel A ^b,c,d   Morrill, Gregory B ^a  

^a PFIZER INC   (United States)

^b U S PUBLIC HEALTH SERVICE   (United States)

^c PHOENIX INDIAN MEDICAL CENTER   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

American Indian; Celecoxib; Cyclooxygenase inhibitors; Hypertension; Rofecoxib

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; CLONIDINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ROFECOXIB; SPIRONOLACTONE;

ADULT; AGED; AMERICAN INDIAN; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULARY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DYSPNEA; EDEMA; FEMALE; HEALTH SERVICE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; STUDENT T TEST; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARIZONA; BLOOD PRESSURE; CHEMISTRY, PHARMACEUTICAL; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; HYPERTENSION; INDIANS, NORTH AMERICAN; LACTONES; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; PYRAZOLES; RETROSPECTIVE STUDIES; SULFONAMIDES; SULFONES;

EID: 17644375154     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E624     Document Type: Article

References (28)

1. Dubois RW, Melmed GY, Henning JM, Laine L. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther 2004;19:197-208.
2. Mamdami M, Rochon PA, Juurlink DN, Kopp A, Anderson GM, Naglie G, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002;325:624-9.
3. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
4. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55.
5. Brinker A, Goldkind L, Bonnel R, Beitz J. Spontaneous reports of hypertension leading to hospitalization in association with rofecoxib, celecoxib, nabumetone and oxaprozin. Drugs Aging 2004;21:479-84.
6. Bresalier RS, Sandler RS, Quan H, Bologonese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. Published online 15 February 2005; DOI 10.1056/NEJMoa050493
7. Nietert PJ, Ornstein SM, Dickerson LM, Rothenberg RJ. Comparison of changes in blood pressure measurements and antihypertensive therapy in older, hypertensive, ambulatory care patients prescribed celecoxib or rofecoxib. Pharmacotherapy 2003;23:1416-23.
8. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001;8:85-95.
9. Whelton A, White WB, Bello AE, Puma JA, Fort JG. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002;90:959-63.
10. Schellhase E, Suryaatmaja E, Evans TS. COX-2 inhibitors: effects on blood pressure in a Veterans Affairs medical center. Hosp Pharm 2003;38:556-64.
11. Cho J, Cooke CE, Proveau W. A retrospective review of the effect of COX-2 inhibitors on blood pressure change. Am J Ther 2003;10:311-7.
12. Howard BV, Lee ET, Cowan LD, Devereux RB, Galloway JM, Go OT, et al. Rising tide of cardiovascular disease in American Indians: the Strong Heart Study. Circulation 1999;99:2389-95.
13. Zhao SZ, Reynolds MW, Lefkowith J, Whelton A, Arellano FM. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. Clin Ther 2001;23:1478-91.
14. Mamdami M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, et al. Cyclo-oxygenase-2 inhibitors versus non-selective anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population based cohort study. Lancet 2004;363:1751-6.
15. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004;109:2068-73.
16. Topol EJ. Failing the public health - rofecoxib, Merck, and the FDA. N Engl J Med 2004;351:1707-9.
17. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-11.
18. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
19. Graham DJ, Campen DH, Cheetham C, Hui R, Spence M, Ray WA. Risk of acute myocardial infarction and sudden death with use of COX-2 selective and non-selective NSAIDs. Presented at the 20th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Bordeaux, France, August 22-25, 2004.
20. Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, et al. Rofecoxib: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 1999;290:551-60.
21. Niederberger E, Manderscheid C, Grosch S, Schmidt H, Ehnert C, Geisslinger G. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem Pharmacol 2004;68:341-50.
22. Walter MF, Jacob RF, Day CA, Dahlborg R, Weng Y, Mason RP. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 2004;177:235-43.
23. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, Fitzgerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999;96:272-7.
24. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. Published online 15 February 2005; DOI 10.1056/NEJMoa050405
25. NIH News. National Institutes of Health. www.nih.gov/news/pr/dec2004/od- 20.htm (accessed 2004 Dec 23).
26. Cardiovascular Safety Review. Food and Drug Administration. www.fda. gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf (accessed 2004 Oct 5).
27. Wolfe F, Zhao S, Reynolds M, Pettitt D. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal anti-inflammatory drugs and nonusers of NSAID receiving ordinary clinical care. J Rheumatol 2004;31:1143-51.
28. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial. JAMA 2000;283:1967-75.